ALVO Stock Analysis: Buy, Sell, or Hold?
ALVO - Alvotech Ordinary Shares
$3.26
0.06 (1.87%)
▲
5d:
-5.78%
30d:
-9.44%
90d:
-36.33%
HOLD
LOW Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALVO trades at premium valuation expecting 8.4% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: ALVO trades at premium valuation expecting 8.4% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $3.26, which is considered oversold relative to its 30-day fair value range of $3.36 to $3.65. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.8) compared to its historical average (14.0). At these levels, the market is pricing in 8.4% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong downtrend. The price is currently testing key support at $3.17. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.83 (+324.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALVO is in a strong downtrend. The price is currently testing key support at $3.17. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.83 (+324.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.36 -
$3.65
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 324.3% below Wall St target ($13.83)
- BULLISH: Expecting earnings turnaround to 8.4% growth with 10.1% revenue growth
- CAUTION: Recommendation downgraded due to -5.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.36 -
$3.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.17
Resistance Level
$3.61
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.81
Wall Street Target
$13.83
(+324.3%)
Revenue Growth (YoY)
10.1%
Earnings Growth (YoY)
-58.4%
Profit Margin
4.7%
Valuation Premium vs History
+8.4% premium
PE vs Historical
17.8 vs 14.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.4%
(market-implied from PE analysis)
1-Year Target
$3.53
(+8%)
2-Year Target
$3.83
(+18%)
3-Year Target
$4.15
(+27%)
3-Yr Target (if PE normalizes)
(PE: 18→14)
PE COMPRESSION
$3.26
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 2804.8%)
$13.55
(+316%)
Base:
(SPY PE: 17.8, Growth: 2804.8%)
$11.00
(+238%)
Bear:
(PE: 14.0, Growth: 2804.8%)
$8.65
(+165%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 32.00 | Current EPS (TTM): $0.10
Bull Case
$6.44
(+98%)
Analyst growth 83.0%, PE expands to 35.2
Base Case
$5.86
(+80%)
Market implied 83.0%, PE stable at 32.0
Bear Case
$2.18
(-33%)
Severe decline -20.0%, PE contracts to 27.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 09, 2026 2:59 AM ET
Data refreshes hourly during market hours. Next update: 3:59 AM
Data refreshes hourly during market hours. Next update: 3:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 66 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$96 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$149 | 52 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |
